


1fw



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Meade, C. et al.) Art Unit: 1614
 U.S. Appln. No. : 10/611,717) Examiner: Spivack, P.G.
 Confirmation No. : 7385
 U.S. Filing Date : 07/01/2003
 Title of Invention : New pharmaceutical compositions based on novel anticholinergics
 and p38 kinase inhibitors
 Attny. Docket No.: 1/1366

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Response to Restriction Requirement


Sir:

This paper is in response to the restriction requirement dated 06/09/2004.

In the restriction requirement, the Examiner has required election of a single species for examination purposes.

Applicants hereby elect without traverse the following species:

Example 1, page 162:




1-[5-*tert*-butyl-2-*p*-tolyl-2*H*-pyrazol-3-yl]-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea.


Claims 1-6 in-part, 10, 15-27 in-part.

Applicants respectfully request that the Examiner identify the scope of the search in the next paper in order to facilitate applicants filing any necessary divisional applications.

Applicants reserve the right to file in one or more divisional applications any nonelected subject matter in this case without prejudice under 35 USC 121.

Certificate of Mailing Under 37 C.F.R. § 1.8(a)
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Anthony P. Bottino
Reg. No. 41,629


7/2/2004

Dated

Respectfully submitted,



Anthony P. Bottino
Registration No. 41,629
Attorney for Applicants

BOEHRINGER INGELHEIM CORPORATION
Patent Department
900 Ridgebury Road/P.O. Box 368
Ridgefield, CT 06877
Telephone: (203) 791-6764
Facsimile: (203) 798-4408